{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T23:37:12Z","timestamp":1794872232738,"version":"4.9.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2020M3A9E403869513"],"award-info":[{"award-number":["2020M3A9E403869513"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-50660-y","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T23:46:34Z","timestamp":1722555994000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0038-3959","authenticated-orcid":false,"given":"Byung-Kwan","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4837-0436","authenticated-orcid":false,"given":"Won-Il","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonsuk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieun","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6351-7355","authenticated-orcid":false,"given":"Jung Kuk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5514-4189","authenticated-orcid":false,"given":"Young Seok","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8388-1840","authenticated-orcid":false,"given":"Pilhan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Ah","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6324-2224","authenticated-orcid":false,"given":"Jun Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6652-1349","authenticated-orcid":false,"given":"Hail","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,2]]},"reference":[{"key":"50660_CR1","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79, 1542\u20131556 (2023).","journal-title":"J. Hepatol."},{"key":"50660_CR2","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell, E. E., Wong, V. W. S. & Rinella, M. Non-alcoholic fatty liver disease. Lancet 397, 2212\u20132224 (2021).","journal-title":"Lancet"},{"key":"50660_CR3","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","volume":"29","author":"ML Teng","year":"2023","unstructured":"Teng, M. L. et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 29, S32\u2013S42 (2023).","journal-title":"Clin. Mol. Hepatol."},{"key":"50660_CR4","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64, 1577\u20131586 (2016).","journal-title":"Hepatology"},{"key":"50660_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang, D. Q., El-Serag, H. B. & Loomba, R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 18, 223\u2013238 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"50660_CR6","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/liv.14825","volume":"41","author":"JM Schattenberg","year":"2021","unstructured":"Schattenberg, J. M. et al. Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. Liver Int. 41, 1227\u20131242 (2021).","journal-title":"Liver Int."},{"key":"50660_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cmet.2018.10.012","volume":"29","author":"MA Febbraio","year":"2019","unstructured":"Febbraio, M. A. et al. Preclinical models for studying NASH-driven HCC: How useful are they? Cell Metab. 29, 18\u201326 (2019).","journal-title":"Cell Metab."},{"key":"50660_CR8","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J. Hepatol. 71, 793\u2013801 (2019).","journal-title":"J. Hepatol."},{"key":"50660_CR9","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.31014","volume":"71","author":"F Kanwal","year":"2020","unstructured":"Kanwal, F. et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology 71, 808\u2013819 (2020).","journal-title":"Hepatology"},{"key":"50660_CR10","doi-asserted-by":"publisher","first-page":"e1003100","DOI":"10.1371\/journal.pmed.1003100","volume":"17","author":"H Jarvis","year":"2020","unstructured":"Jarvis, H. et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med. 17, e1003100 (2020).","journal-title":"PLoS Med."},{"key":"50660_CR11","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.2337\/dc22-2048","volume":"46","author":"L Castera","year":"2023","unstructured":"Castera, L. et al. High prevalence of NASH and advanced fibrosis in Type 2 Diabetes: A prospective study of 330 outpatients undergoing liver biopsies for elevated ALT, using a low threshold. Diab. Care 46, 1354\u20131362 (2023).","journal-title":"Diab. Care"},{"key":"50660_CR12","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","volume":"78","author":"V Ajmera","year":"2023","unstructured":"Ajmera, V. et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J. Hepatol. 78, 471\u2013478 (2023).","journal-title":"J. Hepatol."},{"key":"50660_CR13","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella, M. E. et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 77, 1797\u20131835 (2023).","journal-title":"Hepatology"},{"key":"50660_CR14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas, J. P. et al. Tirzepatide versus Semaglutide once weekly in patients with Type 2 diabetes. N. Engl. J. Med. 385, 503\u2013515 (2021).","journal-title":"N. Engl. J. Med."},{"key":"50660_CR15","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","volume":"402","author":"WT Garvey","year":"2023","unstructured":"Garvey, W. T. et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 402, 613\u2013626 (2023).","journal-title":"Lancet"},{"key":"50660_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205\u2013216 (2022).","journal-title":"N. Engl. J. Med."},{"key":"50660_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","volume":"10","author":"A Gastaldelli","year":"2022","unstructured":"Gastaldelli, A. et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diab. Endocrinol. 10, 393\u2013406 (2022).","journal-title":"Lancet Diab. Endocrinol."},{"key":"50660_CR18","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1210\/er.2019-00034","volume":"40","author":"MJ Watt","year":"2019","unstructured":"Watt, M. J., Miotto, P. M., De Nardo, W. & Montgomery, M. K. The Liver as an Endocrine Organ - Linking NAFLD and Insulin Resistance. Endocr. Rev. 40, 1367\u20131393 (2019).","journal-title":"Endocr. Rev."},{"key":"50660_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/hep4.1789","volume":"6","author":"S Subudhi","year":"2022","unstructured":"Subudhi, S. et al. Distinct hepatic gene-expression patterns of NAFLD in patients with obesity. Hepatol. Commun. 6, 77\u201389 (2022).","journal-title":"Hepatol. Commun."},{"key":"50660_CR20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.14740\/gr1110","volume":"11","author":"AM Olofson","year":"2018","unstructured":"Olofson, A. M., Gonzalo, D. H., Chang, M. & Liu, X. Steatohepatitic variant of hepatocellular carcinoma: a focused review. Gastroenterol. Res. 11, 391\u2013396 (2018).","journal-title":"Gastroenterol. Res."},{"key":"50660_CR21","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1097\/PAS.0b013e3181f31caa","volume":"34","author":"M Salomao","year":"2010","unstructured":"Salomao, M., Yu, W. M., Brown, R. S., Emond, J. C. & Lefkowitch, J. H. Steatohepatitic hepatocellular carcinoma (SH-HCC): A distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD\/NASH. Am. J. Surg. Pathol. 34, 1630\u20131636 (2010).","journal-title":"Am. J. Surg. Pathol."},{"key":"50660_CR22","doi-asserted-by":"publisher","first-page":"15539","DOI":"10.3748\/wjg.v20.i42.15539","volume":"20","author":"Y Takahashi","year":"2014","unstructured":"Takahashi, Y. Histopathology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J. Gastroenterol. 20, 15539 (2014).","journal-title":"World J. Gastroenterol."},{"key":"50660_CR23","doi-asserted-by":"publisher","first-page":"15955","DOI":"10.3748\/wjg.v20.i43.15955","volume":"20","author":"M Schlageter","year":"2014","unstructured":"Schlageter, M., Terracciano, L. M., D\u2019Angelo, S. & Sorrentino, P. Histopathology of hepatocellular carcinoma. World J. Gastroenterol. 20, 15955 (2014).","journal-title":"World J. Gastroenterol."},{"key":"50660_CR24","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1369\/0022155413492771","volume":"61","author":"S Yao","year":"2013","unstructured":"Yao, S. et al. Diagnostic value of immunohistochemical staining of GP73, GPC3, DCP, CD34, CD31, and Reticulin staining in Hepatocellular Carcinoma. J. Histochem. Cytochem. 61, 639\u2013648 (2013).","journal-title":"J. Histochem. Cytochem."},{"key":"50660_CR25","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/hep.29254","volume":"66","author":"R D\u00e9sert","year":"2017","unstructured":"D\u00e9sert, R. et al. Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection. Hepatology 66, 1502\u20131518 (2017).","journal-title":"Hepatology"},{"key":"50660_CR26","doi-asserted-by":"publisher","first-page":"7385","DOI":"10.1158\/0008-5472.CAN-09-1089","volume":"69","author":"Y Hoshida","year":"2009","unstructured":"Hoshida, Y. et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res. 69, 7385\u20137392 (2009).","journal-title":"Cancer Res."},{"key":"50660_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/hep.21467","volume":"45","author":"S Boyault","year":"2007","unstructured":"Boyault, S. et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45, 42\u201352 (2007).","journal-title":"Hepatology"},{"key":"50660_CR28","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.jhep.2021.04.049","volume":"75","author":"R Pinyol","year":"2021","unstructured":"Pinyol, R. et al. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J. Hepatol. 75, 865\u2013878 (2021).","journal-title":"J. Hepatol."},{"key":"50660_CR29","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/hep.27732","volume":"61","author":"A Villanueva","year":"2015","unstructured":"Villanueva, A. et al. DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology 61, 1945\u20131956 (2015).","journal-title":"Hepatology"},{"key":"50660_CR30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.20892\/j.issn.2095-3941.2019.0335","volume":"17","author":"Q Wang","year":"2020","unstructured":"Wang, Q. et al. Time serial transcriptome reveals Cyp2c29 as a key gene in hepatocellular carcinoma development. Cancer Biol. Med 17, 401\u2013417 (2020).","journal-title":"Cancer Biol. Med"},{"key":"50660_CR31","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/dom.14322","volume":"23","author":"B Cariou","year":"2021","unstructured":"Cariou, B., Byrne, C. D., Loomba, R. & Sanyal, A. J. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diab. Obes. Metab. 23, 1069\u20131083 (2021).","journal-title":"Diab. Obes. Metab."},{"key":"50660_CR32","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jhep.2010.10.039","volume":"55","author":"L Lo","year":"2011","unstructured":"Lo, L. et al. Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis. J. Hepatol. 55, 435\u2013444 (2011).","journal-title":"J. Hepatol."},{"key":"50660_CR33","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00795-013-0016-1","volume":"46","author":"M Fujii","year":"2013","unstructured":"Fujii, M. et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol. Morphol. 46, 141\u2013152 (2013).","journal-title":"Med Mol. Morphol."},{"key":"50660_CR34","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1002\/hep.30333","volume":"69","author":"G Farrell","year":"2019","unstructured":"Farrell, G. et al. Mouse models of nonalcoholic steatohepatitis: toward optimization of their relevance to human nonalcoholic steatohepatitis. Hepatology 69, 2241\u20132257 (2019).","journal-title":"Hepatology"},{"key":"50660_CR35","first-page":"704045","volume":"2008","author":"M Zhang","year":"2008","unstructured":"Zhang, M., Lv, X. Y., Li, J., Xu, Z. G. & Chen, L. The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp. Diab. Res 2008, 704045 (2008).","journal-title":"Exp. Diab. Res"},{"key":"50660_CR36","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.phrs.2005.05.004","volume":"52","author":"K Srinivasan","year":"2005","unstructured":"Srinivasan, K., Viswanad, B., Asrat, L., Kaul, C. L. & Ramarao, P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening. Pharm. Res 52, 313\u2013320 (2005).","journal-title":"Pharm. Res"},{"key":"50660_CR37","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1053\/meta.2000.17721","volume":"49","author":"MJ Reed","year":"2000","unstructured":"Reed, M. J. et al. A new rat model of type 2 diabetes: The fat-fed, streptozotocin-treated rat. Metabolism 49, 1390\u20131394 (2000).","journal-title":"Metabolism"},{"key":"50660_CR38","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S0278-6915(02)00014-5","volume":"40","author":"A Imaeda","year":"2002","unstructured":"Imaeda, A., Kaneko, T., Aoki, T., Kondo, Y. & Nagase, H. DNA damage and the effect of antioxidants in streptozotocin-treated mice. Food Chem. Toxicol. 40, 979\u2013987 (2002).","journal-title":"Food Chem. Toxicol."},{"key":"50660_CR39","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.etp.2004.11.001","volume":"56","author":"E Kume","year":"2005","unstructured":"Kume, E. et al. Morphological and gene expression analysis in mouse primary cultured hepatocytes exposed to streptozotocin. Exp. Toxicol. Pathol. 56, 245\u2013253 (2005).","journal-title":"Exp. Toxicol. Pathol."},{"key":"50660_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3350\/cmh.2022.0058","volume":"29","author":"G Zou","year":"2023","unstructured":"Zou, G. & Park, J. I. Wnt signaling in liver regeneration, disease, and cancer. Clin. Mol. Hepatol. 29, 33\u201350 (2023).","journal-title":"Clin. Mol. Hepatol."},{"key":"50660_CR41","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.apsb.2021.09.019","volume":"12","author":"D Du","year":"2022","unstructured":"Du, D. et al. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm. Sin. B 12, 558\u2013580 (2022).","journal-title":"Acta Pharm. Sin. B"},{"key":"50660_CR42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0168-8278(02)00073-9","volume":"37","author":"S Seki","year":"2002","unstructured":"Seki, S. et al. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J. Hepatol. 37, 56\u201362 (2002).","journal-title":"J. Hepatol."},{"key":"50660_CR43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.mrfmmm.2011.11.001","volume":"736","author":"MA Schults","year":"2012","unstructured":"Schults, M. A. et al. Decreased nucleotide excision repair in steatotic livers associates with myeloperoxidase-immunoreactivity. Mutat. Res. - Fundam. Mol. Mech. Mutagen. 736, 75\u201381 (2012).","journal-title":"Mutat. Res. - Fundam. Mol. Mech. Mutagen."},{"key":"50660_CR44","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00535-012-0739-0","volume":"48","author":"S Tanaka","year":"2013","unstructured":"Tanaka, S. et al. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. J. Gastroenterol. 48, 1249\u20131258 (2013).","journal-title":"J. Gastroenterol."},{"key":"50660_CR45","doi-asserted-by":"publisher","first-page":"5155","DOI":"10.1038\/s41388-021-01950-y","volume":"40","author":"MK Brahma","year":"2021","unstructured":"Brahma, M. K. et al. Oxidative stress in obesity-associated hepatocellular carcinoma: sources, signaling and therapeutic challenges. Oncogene 40, 5155\u20135167 (2021).","journal-title":"Oncogene"},{"key":"50660_CR46","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321 (2005).","journal-title":"Hepatology"},{"key":"50660_CR47","doi-asserted-by":"publisher","first-page":"7918","DOI":"10.1364\/BOE.442608","volume":"12","author":"J Moon","year":"2021","unstructured":"Moon, J. et al. Intravital two-photon imaging and quantification of hepatic steatosis and fibrosis in a live small animal model. Biomed. Opt. Express 12, 7918 (2021).","journal-title":"Biomed. Opt. Express"},{"key":"50660_CR48","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1039\/c2cc17496k","volume":"48","author":"E Kim","year":"2012","unstructured":"Kim, E., Lee, S. & Park, S. B. A Seoul-Fluor-based bioprobe for lipid droplets and its application in image-based high throughput screening. Chem. Commun. 48, 2331 (2012).","journal-title":"Chem. Commun."},{"key":"50660_CR49","doi-asserted-by":"publisher","first-page":"064010","DOI":"10.1117\/1.3041159","volume":"13","author":"W Sun","year":"2008","unstructured":"Sun, W. et al. Nonlinear optical microscopy: use of second harmonic generation and two-photon microscopy for automated quantitative liver fibrosis studies. J. Biomed. Opt. 13, 064010 (2008).","journal-title":"J. Biomed. Opt."},{"key":"50660_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"50660_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li, B. & Dewey, C. N. RSEM: Accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinforma. 12, 323 (2011).","journal-title":"BMC Bioinforma."},{"key":"50660_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"50660_CR53","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov, M. V. et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90\u2013W97 (2016).","journal-title":"Nucleic Acids Res."},{"key":"50660_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen, E. Y. et al. Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinforma. 14, 128 (2013).","journal-title":"BMC Bioinforma."},{"key":"50660_CR55","doi-asserted-by":"publisher","first-page":"e1195","DOI":"10.1371\/journal.pone.0001195","volume":"2","author":"Y Hoshida","year":"2007","unstructured":"Hoshida, Y., Brunet, J. P., Tamayo, P., Golub, T. R. & Mesirov, J. P. Subclass mapping: Identifying common subtypes in independent disease data sets. PLoS One 2, e1195 (2007).","journal-title":"PLoS One"},{"key":"50660_CR56","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk, D. et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47, D607\u2013D613 (2019).","journal-title":"Nucleic Acids Res."},{"key":"50660_CR57","doi-asserted-by":"publisher","first-page":"e1008239","DOI":"10.1371\/journal.pcbi.1008239","volume":"16","author":"A Singhal","year":"2020","unstructured":"Singhal, A. et al. Multiscale community detection in cytoscape. PLoS Comput. Biol. 16, e1008239 (2020).","journal-title":"PLoS Comput. Biol."},{"key":"50660_CR58","doi-asserted-by":"publisher","first-page":"e18961","DOI":"10.1371\/journal.pone.0018961","volume":"6","author":"A Lancichinetti","year":"2011","unstructured":"Lancichinetti, A., Radicchi, F., Ramasco, J. J. & Fortunato, S. Finding statistically significant communities in networks. PLoS One 6, e18961 (2011).","journal-title":"PLoS One"},{"key":"50660_CR59","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon, P. et al. Cytoscape: A software Environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498\u20132504 (2003).","journal-title":"Genome Res."},{"key":"50660_CR60","doi-asserted-by":"publisher","first-page":"W191","DOI":"10.1093\/nar\/gkz369","volume":"47","author":"U Raudvere","year":"2019","unstructured":"Raudvere, U. et al. G:Profiler: A web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 47, W191\u2013W198 (2019).","journal-title":"Nucleic Acids Res."},{"key":"50660_CR61","doi-asserted-by":"publisher","first-page":"iyad031","DOI":"10.1093\/genetics\/iyad031","volume":"224","author":"C Gene Ontology","year":"2023","unstructured":"Gene Ontology, C. et al. The Gene Ontology knowledgebase in 2023. Genetics 224, iyad031 (2023).","journal-title":"Genetics"},{"key":"50660_CR62","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner, M. et al. Gene ontology: Tool for the unification of biology. Nat. Genet. 25, 25\u201329 (2000).","journal-title":"Nat. Genet."},{"key":"50660_CR63","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"50660_CR64","unstructured":"Krueger, F., James, F., Ewels, P., Afyounian, E. & Schuster-Boeckler, B. TrimGalore. Babraham Bioinformatics (2021)."},{"key":"50660_CR65","unstructured":"Andrews, S. FastQC. Babraham Bioinformatics (2010)."},{"key":"50660_CR66","doi-asserted-by":"crossref","unstructured":"Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nature Methods. Nature Publishing Group (2012).","DOI":"10.1038\/nmeth.1923"},{"key":"50660_CR67","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giab008","volume":"10","author":"P Danecek","year":"2021","unstructured":"Danecek, P. et al. Twelve years of SAMtools and BCFtools. Gigascience 10, giab008 (2021).","journal-title":"Gigascience"},{"key":"50660_CR68","unstructured":"Institute, B. Picard toolkit. Broad Institute, GitHub repository (2019)."},{"key":"50660_CR69","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","volume":"26","author":"AR Quinlan","year":"2010","unstructured":"Quinlan, A. R. & Hall, I. M. BEDTools: A flexible suite of utilities for comparing genomic features. Bioinformatics 26, 841\u2013842 (2010).","journal-title":"Bioinformatics"},{"key":"50660_CR70","doi-asserted-by":"crossref","unstructured":"Gaspar, J. M. Improved peak-calling with MACS2. bioRxiv (2018).","DOI":"10.1101\/496521"},{"key":"50660_CR71","unstructured":"Stark, R. & Brown, G. DiffBind: differential binding analysis of ChIP-Seq peak data. Bioconductor (2011)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50660-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50660-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50660-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T11:04:04Z","timestamp":1729767844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-50660-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,2]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["50660"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-50660-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,2]]},"assertion":[{"value":"28 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments complied with the relevant ethical regulations. Experimental protocols for this study were approved by the Institutional Animal Care and Use Committee of Korea Advanced Institute of Science and Technology (KAIST). The criteria for terminating the animal experiment were set as follows: if the size of the hepatic tumor measured externally in the mice exceeded a maximum diameter of 20\u2009mm, or if the weight loss was more than 20%. Only one mouse had a tumor size that exceeded the maximum diameter, measuring 21\u2009mm, which was within the margin of human error. Each week, the surface skin of the mouse liver was visually inspected and palpated to assess tumorigenesis, and the weight was measured to ensure compliance with these criteria. Experiments using human specimens were performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki and written informed consent was obtained from each participant. There was no compensation provided to research subjects for their participation. The study protocol was approved by the Severance Hospital Institutional Review Board (IRB No. 4-2018-0537, Seoul, Korea).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6506"}}